Publications Benefit-Risk Assessment of Vedolizumab in the Treatment of Crohn’s Disease and Ulcerative Colitis Citation Battat R, Ma C, Jairath V, Khanna R, Feagan BG. Benefit-Risk Assessment of Vedolizumab in the Treatment of Crohn's Disease and Ulcerative Colitis. Drug Saf. 2019 May;42(5):617-632. doi: 10.1007/s40264-018-00783-1. PMID: 30830573. Abstract Vedolizumab, a humanized monoclonal antibody to the α4β7 integrin, reduces lymphocyte trafficking to the intestine. Tags Adverse Effects, Antibodies, Crohn's Disease, Drug Therapy, Gastrointestinal Agents, Monoclonal, therapeutic use, Ulcerative Colitis Read More
